* SpringWorks Therapeutics Inc SWTX.OQ SWTX.O is
expected
to show a rise in quarterly revenue when it reports results
* The Stamford Connecticut-based company is expected to
report
revenue of $200 thousand, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for SpringWorks
Therapeutics
Inc is for a loss of $1.33 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for SpringWorks
Therapeutics Inc is $47, above its last closing price
of $21.61.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -1.25 -1.26 -1.25 Beat 1
Mar. 31 2023 -1.31 -1.25 -1.18 Beat 5.9
Dec. 31 2022 -1.22 -1.22 -1.17 Beat 4.2
Sep. 30 2022 -1.30 -1.32 -1.37 Missed -3.8
Jun. -1.22 -1.20 -1.41 Missed -17.2
30 2022
Mar. 31 2022 -1.07 -1.02 -1.26 Missed -23.1
Dec. 31 2021 -0.88 -0.88 -1.15 Missed -31
Sep. 30 2021 -0.80 -0.76 -0.84 Missed -10.2
This summary was machine generated October 30 at 17:33 GMT. All
figures in US dollars unless otherwise stated